Agent Orange linked to nonmelanotic invasive skin cancer

Nonmelanotic Invasive Skin Cancer Tied to Agent Orange
Nonmelanotic Invasive Skin Cancer Tied to Agent Orange

(HealthDay News) -- Agent Orange (2,3,7,8-tetrachlorodibenzodioxin) exposure is associated with increased incidence of nonmelanotic invasive skin cancer, according to research published in the February issue of Plastic and Reconstructive Surgery.

Mark W. Clemens, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues retrospectively reviewed the medical records of 100 consecutive male patients (mean age, 65.7 years) who enrolled in the Agent Orange registry at the Veterans Affairs Hospital of Washington, D.C., between August of 2009 and January of 2010.

The researchers found that 2,3,7,8-tetrachlorodibenzodioxin exposure occurred in 56 percent by living or working in contaminated areas, in 30 percent by actively spraying it, and in 14 percent by traveling in contaminated areas. Nonmelanotic invasive skin cancer was seen in 51 percent of patients, chloracne in 43 percent, and other malignancies in 26 percent (including prostate, colon, or bladder cancer). The national age-matched incidence rate for nonmelanotic invasive skin cancer was significantly lower than that seen in the study population (23.8 versus 51 percent; P < 0.001). A decreased incidence of the cancer was seen in those with a high Fitzpatrick skin type score (P = 0.010) and dark eye color (P = 0.036), but exposure by active spraying (P = 0.003) and presence of chloracne (P < 0.001) were associated with increased nonmelanotic invasive skin cancer incidence rates.

"2,3,7,8-tetrachlorodibenzodioxin exposure appears to be associated with the development of nonmelanotic invasive skin cancer," the authors write.

Full Text

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs